Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | PRKACG | P22612 | 1/20 | 0.49 |
| ▸ | PRKACB | P22694 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | PRCP | P42785 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.35 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333528 | 1.00 | PRKACA (0.49) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL1335278 | 1.00 | PRKACA (0.49) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| Hydrochloric Acid SCHEMBL1849039 | 0.98 | PRKACA (0.48) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| Trifluoroacetic Acid SCHEMBL14829349 | 0.86 | KDM1A (0.44) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL14839568 | 0.85 | KCNH2 (0.43) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL2602789 | 0.82 | SLC6A2 (0.44) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL280628 | 0.81 | CSNK1D (0.43) | PRKACAPRKACGPRKACBPRCPCTSK | |
| Hydrochloric Acid SCHEMBL537239 | 0.81 | SLC6A2 (0.43) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL22589151 | 0.81 | CHRNA7 (0.47) | PRKACAPRKACGPRKACBSLC6A2SLC6A3 | |
| SCHEMBL21717791 | 0.81 | MAPT (0.44) | PRKACAPRKACGPRKACBCTSKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1049431-C | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 2000-02-16 | — | — | CN | claimed |
| EP-4747245-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20250019373-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | VORONOI INC. (KR) | 2025-01-16 | — | — | US | disclosed |
| EP-4050005-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4421077-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | Voronoi Inc. (KR) | 2024-08-28 | — | — | EP | disclosed |
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2024-03-21 | — | — | US | disclosed |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | CYTOKINETICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-11-07 | — | — | US | disclosed |
| EP-4219500-A1 | CONDENSED HETEROCYCLIC COMPOUND | Nissan Chemical Corporation (JP) | 2023-08-02 | — | — | EP | disclosed |
| CN-115806550-A | Bicyclic BET bromodomain inhibitors and uses thereof | 康威基内有限公司 | 2023-03-17 | — | — | CN | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | disclosed |
| EP-1448555-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | Celltech R & D Limited (GB) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045941-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2003-06-05 | — | — | WO | disclosed |
| CN-1075812-C | Prodrugs of morpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 2001-12-05 | — | — | CN | disclosed |
| CN-1049431-C | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 2000-02-16 | — | — | CN | disclosed |
| CN-1147254-A | Prodrugs of morpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1997-04-09 | — | — | CN | disclosed |
| EP-0748320-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995023798-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | NAMPT, NNT, NAPRT | PRKACA 1785/4885PRKACG 1554/4885PRKACB 1031/4885 |
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | SPR, QDPR, SUCNR1 | PRKACA 4079/4885PRKACG 3939/4885PRKACB 4095/4885 |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | USP19, USP16, USP18 | PRKACA 3663/4885PRKACG 3730/4885PRKACB 3711/4885 |
| US-20250019373-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | RIPK1, RIPK2, RIPK3 | PRKACA 147/4885PRKACG 250/4885PRKACB 210/4885 |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | ROR1, MAPK1, IRAK1 | PRKACA 2529/4885PRKACG 3129/4885PRKACB 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.